<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204408</url>
  </required_header>
  <id_info>
    <org_study_id>NN7769-4513</org_study_id>
    <secondary_id>U1111-1227-4220</secondary_id>
    <secondary_id>2019-000465-20</secondary_id>
    <nct_id>NCT04204408</nct_id>
  </id_info>
  <brief_title>A Research Study Investigating Mim8 in People With Haemophilia A</brief_title>
  <acronym>FRONTIER1</acronym>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Doses of NNC0365-3769 (Mim8) in Healthy Subjects and in Subjects With Haemophilia A With or Without Factor VIII Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of 2 parts. Part 1 looks at the safety and tolerability when the study&#xD;
      medicine Mim8 is given to healthy subjects for the first time. The obtained results will help&#xD;
      to perform a second part of the study with patients who suffer from a bleeding disorder&#xD;
      called haemophilia A. Haemophilia A is an inherited condition caused by a lack of a protein&#xD;
      called factor VIII. Mim8 works in the body for a longer time than most other products used by&#xD;
      patients with haemophilia A. Mim8 is designed for once weekly or once monthly administration.&#xD;
      In Part 1, participants will be injected only once with either Mim8 or a &quot;dummy&quot; medicine&#xD;
      (placebo) under the tummy skin - which one will be decided by chance. In this study, Mim8&#xD;
      will be used for the first time in humans. Mim8 is a new medicine and cannot be prescribed by&#xD;
      doctors in any country. Mim8 belongs to a group of medicines called antibodies. Mim8 is&#xD;
      designed to take over the function of the missing factor VIII in haemophilia A patients. Part&#xD;
      1 of the study will last for up to 20 weeks. Participants will attend a screening visit,&#xD;
      followed by a 12-day in-house visit where they will have to stay in the study unit. This is&#xD;
      followed by 10 ambulatory visits with the study doctor throughout the remaining part of the&#xD;
      study. Assessments will include several blood tests and electrocardiograms (ECGs). In part 2&#xD;
      of the study, people with haemophilia A - with or without inhibitors - will be given&#xD;
      injections with a thin needle in the skin of their stomach, either weekly or monthly. Part 2&#xD;
      of the study will last for 120 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">January 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 placebo-controlled double-blind within cohorts (phase 1) Part 2 open-label (phase 2)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of treatment emergent adverse events</measure>
    <time_frame>From time of dosing (Day 1) to Week 16</time_frame>
    <description>Count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of treatment emergent adverse events</measure>
    <time_frame>From time of first dosing (Day 1) to Week 12</time_frame>
    <description>Count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, extension: Number of treatment emergent adverse events</measure>
    <time_frame>From Week 12 up to Week 120 (16 weeks after last dose)</time_frame>
    <description>Count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of injection site reactions</measure>
    <time_frame>From time of dosing (Day 1) to Week 16</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Relative change in D-dimer</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Relative change in prothrombin fragment 1 and 2</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Relative change in fibrinogen</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Relative change in platelets</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax, SD: the maximum concentration of Mim8 after a single dose</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>μg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-inf, SD: the area under the Mim8 concentration-time curve from time 0 to infinity after a single dose</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>μg*day/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: t1/2, SD: the terminal half-life of Mim8 after a single dose</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: tmax, SD: the time to maximum concentration of Mim8 after a single dose</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change in activated partial thromboplastin time</measure>
    <time_frame>From baseline (Day 1) to Week 16</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly and monthly dosing): Number of injection site reactions</measure>
    <time_frame>From time of first dosing (Day 1) to Week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly and monthly dosing): Occurrence of anti-Mim8 antibodies</measure>
    <time_frame>From baseline (Day 1) to Week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly and monthly dosing): Relative change in D-dimer</measure>
    <time_frame>From baseline (Day 1) to Week 12</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly and monthly dosing): Relative change in prothrombin fragment 1 and 2</measure>
    <time_frame>From baseline (Day 1) to Week 12</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly and monthly dosing): Relative change in fibrinogen</measure>
    <time_frame>From baseline (Day 1) to Week 12</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly and monthly dosing): Relative change in platelets</measure>
    <time_frame>From baseline (Day 1) to Week 12</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 PK session 2 (weekly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses</measure>
    <time_frame>From Day 57 to Day 64</time_frame>
    <description>μg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 PK session 2 (weekly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses</measure>
    <time_frame>From Day 57 to Day 64</time_frame>
    <description>μg*day/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 PK session 2 (monthly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses</measure>
    <time_frame>From Day 57 to Day 85</time_frame>
    <description>μg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 PK session 2 (monthly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses</measure>
    <time_frame>From Day 57 to Day 85</time_frame>
    <description>μg*day/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (weekly dosing): Mean of maximum thrombin generation (peak height)</measure>
    <time_frame>From Day 57 to Day 64</time_frame>
    <description>nM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (monthly dosing): Mean of maximum thrombin generation (peak height)</measure>
    <time_frame>From Day 57 to Day 85</time_frame>
    <description>nM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2, extension: Number of injection site reactions</measure>
    <time_frame>From Week 12 up to Week 120 (16 weeks after last dose)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2, extension: Occurrence of anti-Mim8 antibodies</measure>
    <time_frame>From Week 12 up to Week 120 (16 weeks after last dose)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Haemophilia A With or Without Inhibitors</condition>
  <arm_group>
    <arm_group_label>Single dose (part 1) Mim8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 5 cohorts, 6 participants will receive Mim8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose (part 1) placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded. Single doses in healthy volunteers. In each of the 5 cohorts, 2 participants will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose (part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label. There will be 3 cohorts receiving once-weekly doses (part 2 cohorts 1, 2 and 3) and one cohort receiving once-monthly doses (part 2 cohort 4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0365-3769 A (Mim8)</intervention_name>
    <description>Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses</description>
    <arm_group_label>Multiple dose (part 2)</arm_group_label>
    <arm_group_label>Single dose (part 1) Mim8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Mim8)</intervention_name>
    <description>Mim8 placebo administered subcutaneously (s.c., under the skin)</description>
    <arm_group_label>Single dose (part 1) placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Single ascending dose part 1:&#xD;
&#xD;
          -  Male, aged 18-45 years (both inclusive) at the time of signing informed consent&#xD;
&#xD;
          -  Considered to be generally healthy based on the medical history, physical examination,&#xD;
             and the results of vital signs, electrocardiogram and clinical laboratory tests&#xD;
             performed during the screening visit, as judged by the investigator&#xD;
&#xD;
        Multiple ascending dose part 2:&#xD;
&#xD;
          -  Male, aged 12-64 years (both inclusive) at the time of signing informed consent&#xD;
             (Germany and Japan have local requirements)&#xD;
&#xD;
          -  Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical&#xD;
             records&#xD;
&#xD;
        Exploratory biomarker cohort:&#xD;
&#xD;
          -  Male, aged equal to or above 12 years at the time of signing informed consent (Germany&#xD;
             and Japan have local requirements)&#xD;
&#xD;
          -  Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical&#xD;
             recordsv&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Factor VIII activity equal to or above 150% at screening&#xD;
&#xD;
          -  Increased risk of thrombosis, e.g. known history of personal or first degree&#xD;
             relative(s) with unprovoked deep vein thrombosis&#xD;
&#xD;
          -  Any clinical signs or established diagnosis of venous or arterial thromboembolic&#xD;
             disease&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  Known congenital or acquired coagulation disorders other than haemophilia A&#xD;
&#xD;
          -  Increased risk of thrombosis as evaluated by the investigator. E.g. known history of&#xD;
             personal or first degree relative(s) with unprovoked deep vein thrombosis with&#xD;
             exception of previous catheter-associated thrombosis for which anti-thrombotic&#xD;
             treatment is not currently ongoing&#xD;
&#xD;
          -  Any clinical signs or established diagnosis of venous or arterial thromboembolic&#xD;
             disease with exception of previous catheter-associated thrombosis for which&#xD;
             anti-thrombotic treatment is not currently ongoing&#xD;
&#xD;
          -  Advanced atherosclerotic disease (e.g. known history of ischemic heart disease,&#xD;
             ischemic stroke) as evaluated by the investigator&#xD;
&#xD;
          -  Any autoimmune disease that may increase the risk of thrombosis&#xD;
&#xD;
          -  Receipt of emicizumab or drugs with similar modes of action within 5 half-lives before&#xD;
             trial product administration&#xD;
&#xD;
          -  Ongoing or planned immune tolerance induction therapy&#xD;
&#xD;
        Exploratory biomarker cohort:&#xD;
&#xD;
          -  Known congenital or acquired coagulation disorders other than haemophilia A&#xD;
&#xD;
          -  Increased risk of thrombosis as evaluated by the investigator. E.g. known history of&#xD;
             personal or first degree relative(s) with unprovoked deep vein thrombosis with&#xD;
             exception of previous catheter-associated thrombosis for which anti-thrombotic&#xD;
             treatment is not currently ongoing&#xD;
&#xD;
          -  Any clinical signs or established diagnosis of venous or arterial thromboembolic&#xD;
             disease with exception of previous catheter-associated thrombosis for which&#xD;
             anti-thrombotic treatment is not currently ongoing&#xD;
&#xD;
          -  Advanced atherosclerotic disease (e.g. known history of ischemic heart disease,&#xD;
             ischemic stroke) as evaluated by the investigator&#xD;
&#xD;
          -  Any autoimmune disease that may increase the risk of thrombosis&#xD;
&#xD;
          -  Ongoing or planned immune tolerance induction therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A 6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Parktown, Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

